Innate Pharma Reports 85.27M Shares & Voting Rights as of Jan 1, 2024
Ticker: IPHYF · Form: 6-K · Filed: Jan 12, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jan 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: share-count, voting-rights, regulatory-filing
TL;DR
**Innate Pharma confirmed 85.27 million shares and voting rights as of January 1, 2024.**
AI Summary
Innate Pharma SA, a French biotechnology company, reported its total number of shares and voting rights as of January 1, 2024. This filing, dated January 12, 2024, indicates that the company had 85,270,057 shares outstanding, with a total of 85,270,057 theoretical voting rights and 85,270,057 exercisable voting rights. This matters to investors as it provides transparency on the company's capital structure, which can influence per-share metrics and ownership control.
Why It Matters
This filing provides a clear snapshot of Innate Pharma's capital structure, which is crucial for calculating per-share values and understanding potential dilution or control dynamics for shareholders.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share count and voting rights, presenting no immediate financial risk or operational changes.
Analyst Insight
A smart investor would use this confirmed share count to accurately calculate per-share metrics like EPS or book value when analyzing Innate Pharma's financial performance.
Key Numbers
- 85,270,057 — Total number of shares (as of January 1, 2024)
- 85,270,057 — Total theoretical voting rights (as of January 1, 2024)
- 85,270,057 — Total exercisable voting rights (as of January 1, 2024)
- January 1, 2024 — Effective date of share and voting rights count (the date for which the numbers are reported)
- January 12, 2024 — Date of report and press release (when the 6-K was filed and the press release issued)
Key Players & Entities
- Innate Pharma SA (company) — the registrant filing the 6-K
- Hervé BRAILLY (person) — Chairman of the Executive Board and Chief Executive Officer of Innate Pharma SA
- French Code de Commerce (other) — French commercial law referenced for the disclosure
- French stock-market authorities (other) — regulatory body whose article 223-16 is referenced
Forward-Looking Statements
- Innate Pharma's per-share metrics will be calculated using the 85,270,057 share count for Q1 2024 earnings reports. (Innate Pharma SA) — high confidence, target: Q1 2024 earnings report
FAQ
What is the purpose of Innate Pharma SA's 6-K filing dated January 12, 2024?
The purpose of Innate Pharma SA's 6-K filing dated January 12, 2024, is to report the number of shares and voting rights as of January 1, 2024, in accordance with article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the French stock-market authorities.
How many shares did Innate Pharma SA have outstanding as of January 1, 2024?
As of January 1, 2024, Innate Pharma SA had 85,270,057 shares outstanding.
What were the total theoretical and exercisable voting rights for Innate Pharma SA as of January 1, 2024?
As of January 1, 2024, Innate Pharma SA had 85,270,057 total theoretical voting rights and 85,270,057 total exercisable voting rights.
Who signed the 6-K report on behalf of Innate Pharma SA?
The 6-K report was signed by Hervé BRAILLY, Chairman of the Executive Board and Chief Executive Officer of Innate Pharma SA, on January 12, 2024.
Which exhibit is included in this 6-K filing?
Exhibit 99.1, a Press Release dated January 12, 2024, is included in this 6-K filing, detailing the number of shares and voting rights.
Filing Stats: 219 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-01-12 06:00:08
Filing Documents
- a53881086.htm (6-K) — 9KB
- a53881086ex99_1.htm (EX-99.1) — 10KB
- 0001157523-24-000054.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date: January 12, 2024 By: /s/ Herv BRAILLY Name: Herv BRAILLY Title: Chairman of the Executive Board and Chief Executive Officer